ALLSCRIPTS HLTH (MDRX)
|
User Analysis Rating ALLSCRIPTS-MISY a SELL  | The firm believes that MDRX remains challenged in a tough and competitive operating environment with occasional issues relating to software deployment and a potentially lengthening sales cycle. The Misys Healthcare addition provides an existing customer base that offers MDRX a larger cross-selling opportunity.
| |
| Last edited Fri May 14, 2010 02:27 AM by SudiptaMukherjee (Zacks Investment Research) |  |
|
|
| |
Created by: WikiMigrationBot.
Last Modification: Thursday 03 of June, 2010 08:23:10 CDT by WikiMigrationBot.